PMID: 9449285Feb 4, 1998Paper

Treatment of enterococcal pyelonephritis with trovafloxacin and rifampin: in vitro-in vivo contrast

Antimicrobial Agents and Chemotherapy
J Z Montgomerie, D G Schick

Abstract

The in vitro bactericidal interaction of trovafloxacin and rifampin against Enterococcus spp. has indicated that antagonism occurs between these two antimicrobial agents. This drug combination was examined in vivo in rats with experimental pyelonephritis. The rats received trovafloxacin, rifampin, or both drugs. On the basis of the mean log10 CFU of Enterococcus faecalis from the kidneys, there was no evidence that trovafloxacin and rifampin were antagonistic in vivo.

References

Jul 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G A LosonskyE W Lewis
Feb 1, 1993·Antimicrobial Agents and Chemotherapy·B B Gooding, R N Jones
Feb 1, 1993·Antimicrobial Agents and Chemotherapy·G M EliopoulosR C Moellering
Mar 1, 1996·Antimicrobial Agents and Chemotherapy·R TengT E Liston

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.